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Abstract
Background: Non-invasive prenatal testing (NIPT) is currently used as a frontline screening test to identify fetuses
with common aneuploidies. Occasionally, incidental NIPT results are conveyed to the clinician suggestive of fetuses
with rare chromosome disease syndromes. We describe a child with trisomy 9 (T9) mosaicism where the prenatal
history reported a positive NIPT result for T9 that was unconfirmed by conventional prenatal diagnosis.
Methods: NIPT was performed by low coverage whole genome plasma DNA sequencing. Karyotyping and
fluorescent in situ hybridization (FISH) analysis with chromosome 9p-ter and 9q-ter probes was used to determine
the somatic cell level of T9 mosaicism in the fetus and child. Quantitative fluorescent PCR (Q-PCR) of highly
polymorphic short tandem repeat (STR) chromosome 9 markers was also performed to investigate the nature
of the T9 mosaicism and the parental origin.
Results: A 22 month old girl presented with severe developmental delay, congenital cerebral dysplasia and
congenital heart disease consistent with phenotypes associated with T9 mosaicism syndrome. Review of the
prenatal testing history revealed a positive NIPT result for chromosome T9. However, follow up confirmatory
karyotyping and FISH analysis of fetal cells returned a normal karyotype. Post-natal studies of somatic cell T9
mosaicism by FISH detected levels of approximately 20 % in blood and buccal cells. Q-PCR STR analysis of family
DNA samples suggested that the T9 mosaicism originated by post-zygotic trisomic rescue of a paternal meiotic
II chromosome 9 non-disjunction error resulting in the formation of two distinct somatic cell lines in the proband,
one with paternal isodisomy 9 and one with T9.
Conclusion: This study shows that NIPT may also be a useful screening technology to increase prenatal detection rates
of rare fetal chromosome disease syndromes.
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Background
Prenatal diagnosis by chorionic villous sampling or am-
niocentesis is the gold standard method for detection of
fetal chromosomal abnormalities during pregnancy.
With the advent of next generation sequencing tech-
nologies, it is now possible to detect fetal chromosomal
abnormalities by massively parallel sequencing of the cell
free DNA in the maternal circulation which contains on
average 10–20 % of fetal DNA during the second trimes-
ter [1]. Several large prospective trials [2, 3] have dem-
onstrated that noninvasive prenatal testing (NIPT) is
reliable and accurate with false positive and negative
rates in the range of 0.1–0.2 %. Nonetheless, as the fetal
DNA tested originates from the placental trophoblasts,
it is strongly recommended that all positive NIPT results
are confirmed by invasive prenatal testing [4]. While
NIPT currently focuses on detection of common fetal
autosomal aneuploidies such as T21, T18 and T13 as
well as sex chromosomal aneuploidies, there has been
research reports of positive results including T9 [5] and
T2 [6], suggesting that NIPT may also have clinical util-
ity for detection of rarer fetal trisomies. In this study, we
present a confounding case of T9 mosaicism that was
originally detected by NIPT, but was not confirmed by
traditional invasive prenatal diagnosis methods.
Case presentation
A 22 month old girl presented at our genetic counselling
clinic at the Peking University First Hospital with severe
motor and intellectual disability, recurrent respiratory
infection and failure to thrive. Physical examination re-
vealed severe growth retardation with a weight of 7.5 kg
(<3rd centile 10.9 kg), height of 62 cm (<3rd centile
88.9 cm) and head circumstance of 40 cm (<3rd centile
50 cm). She displayed moderate to severe hypertonia.
Dysmorphic features were visibly evident, including
microcephaly, craniofacial asymmetry, long face, ocular
hypertelorism, short and upward slanting palpebral
fissures, short frenulum of the upper lip, high arched
palate, low-set ears and abnormal nasal features includ-
ing a prominent nasal bridge with a short root, a small
fleshy tip and slit-like nostrils (Fig. 1). X-ray examination
also revealed scoliosis. At 22 months of age, her develop-
mental milestones were only equivalent to normal children
of 7–9 months of age. She could not follow obvious move-
ments with her eyes and struggled to hold her head up.
The parents indicated that she had not developed any form
of speech.
In review of the pregnancy history, maternal serum
screening at 15 weeks gestation revealed a risk for the
Down Syndrome of 1 in 200. Based on this risk, the
couple elected to have confirmatory NIPT at 16 weeks.
Chromosome (Chr) z-scores were 0.62 (Chr21),−0.27
(Chr18) and 0.016 (Chr13), all within the normal z-score
range (−3 < z < 3). However, the z-score for Chr9 (12.92)
was outside the normal range, suggestive of T9. After
calculation of copy number, the percentage of T9 was
30.1 % (Fig. 2a), suggesting T9 mosaicism. The couple’s
clinician was informed about the possibility of a T9 mo-
saic fetus, prompting further prenatal investigation.
No structural anomalies in the second trimester were
evident by ultrasound. However, at 30 gestational
weeks, intrauterine growth restriction and lateral cere-
bral ventriculomegaly (right, 14 mm) was observed. An
echocardiography revealed no cardiac abnormalities.
Further invasive prenatal diagnosis by percutaneous
umbilical blood sampling was therefore performed at
34+2 gestational weeks in order to confirm the sus-
pected T9 mosaicism or the presence of other possible
chromosomal abnormalities. The fetal karyotype deter-
mined by analysis of 20 metaphase cells was 46, XX.
Testing of both parents revealed normal peripheral
blood karyotypes. No further molecular genetic testing
was undertaken.
Fig. 1 Dysmorphic craniofacial features of the proband with trisomy 9 mosaicism syndrome
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The girl was born by vaginal delivery at 41 weeks with
a birth weight of 1960 g, length of 45 cm and head cir-
cumstance of 30 cm (<5th centile 36 cm). The newborn
was referred to the Pediatrics department. Following
ultrasound and MRI assessment, the final clinical diag-
nosis was congenital cerebral dysplasia, intracranial
hemorrhage, thrombocytopenia and congenital heart dis-
ease (ventricular septal defect, patent ductus arteriosus).
Further genetic testing was recommended.
The parental guardians of the child provided written
consent to conduct post-natal genetic testing of the child
at 22 months of age. Peripheral blood karyotyping of
200 metaphase cells identified 199 cells with a normal
46, XX karyotype and one cell with an abnormal 47,
XX,+9 karyotype. Based on guidelines and recommenda-
tions of the International System for Human Cytogenet-
ics Nomenclature [7], this karyotype should normally be
reported as 46, XX. To investigate the presence of T9
mosaicism further, analysis of cultured blood cells with
chromosome 9p-ter and 9q-ter FISH probes detected T9
in 1 of 100 (1 %) cells examined, consistent with karyo-
typing. However, interphase FISH analysis with the same
probes applied to an uncultured peripheral blood smear
revealed T9 in 19 of 100 (19 %) cells examined (Fig. 2b).
To confirm T9 mosaicism in another tissue type,
interphase FISH was also used directly to assess cheek
Fig. 2 Levels of T9 mosaicism in somatic tissues. a. NIPT result for Chr9. The Chr9 plot shows the mean copy number variation per 20 kb sequencing
bin (blue line) versus each 20 kb sequencing bin. The upper dashed line indicates the expected position of the blue line for 100 % T9. b. Analysis of
white blood cells with fluorescein labeled 9p (green) and rhodamine labeled 9q (red) FISH probes. c. Analysis of white blood cells with 9p and 9q FISH
probes. Representative FISH results (B and C) in a single viewing field are shown for two cells as examples of disomy 9 and T9. White arrows indicate
the position of FISH signals for Chr9
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buccal cells. T9 mosaicism was found in 17 of 100 (17 %)
cells examined (Fig. 2c). On this basis, interphase FISH
suggested that the somatic level of T9 mosaicism was
approximately 20 %, differing slightly from the level of
30 % in placental tissue detected by NIPT.
In order to investigate the nature of the T9 mosaicism
and parental origin, we applied quantitative fluorescent
PCR (QF-PCR) to analyse paternal, maternal and pro-
band allelic patterns of short tandem repeat (STR) Chr9
markers. The alleles of STR markers D9S925, D9S1118
and D9S1121 were found to be informative for deter-
mining familial inheritance patterns (Fig. 3). All three
Chr9 STR markers for the proband displayed a skewed
bi-allelic pattern with allelic peak ratios of approximately
10:1 whereas the control D13S325 displayed a bi-allelic
pattern with the expected peak ratio of approximately
1:1. Given that none of the Chr9 STR markers revealed
a tri-allelic pattern typical of trisomy 9, we deduced that
the dominant Chr9 STR allelic peaks were consistent
with inheritance of two identical paternal alleles (iso-
disomy) whilst the minor Chr9 STR allelic peaks were
maternally inherited. Further, since the expected allelic
peak ratio for a full T9 displaying a bi-allelic marker
pattern is 2:1, then the observed peak ratios of approxi-
mately 10:1 suggest a level of around 20 % T9 mosai-
cism, which was very similar to levels determined by
FISH (Fig. 2b and 2c). Taken together, the proband in-
heritance pattern for Chr9 STR markers indicated the
presence of two distinct cell lines in the child, one with
paternal isodisomy 9 in approximately 80 % of somatic
cells and T9 in the remaining somatic cells.
Discussion
T9 syndrome and its related form T9 mosaicism syn-
drome are two extremely rare human chromosomal
disorders. The first babies born with T9 [8] and T9 mo-
saicism [9] were reported in 1973. In the following four
decades there have been sporadic reports in the med-
ical literature of children with T9 [10] or T9 mosaicism
associated with variable levels of somatic mosaicism
ranging from 3 % to 99 % [11]. Children born with T9
usually die following birth or within one year of birth
whereas those born with T9 mosaicism can survive into
adulthood.
Based on data submitted to the tracking rare inci-
dence syndromes (TRIS) project [11] and data pub-
lished by the Rare Chromosomal Disorder Support
Group (www.rarechromo.org), T9 mosaicism is generally
associated with a low birth weight and a wide spectrum of
developmental disabilities, abnormal physical features and
organ pathologies, although the overall disease phenotype
can vary widely between individuals. The main develop-
mental disabilities reported are slow body growth, learning
difficulties and delayed communication and speech. Char-
acteristic physical features include microcephaly, loose
joints, craniofacial abnormalities such as low set ears, cleft
palate as well as skeletal abnormalities of the skull,
hands and feet. Multiple tissue pathologies are common
and can involve different organ systems such as the heart,
kidneys, brain and CNS, the genital and urinary tract,
muscles (hypertonia) and digestive tract. In the T9 mo-
saicism case described in this report, the main disease fea-
tures displayed by the child were dysmorphic craniofacial
Fig. 3 QF-PCR analysis of family genomic DNA samples for revealing the nature and origin of T9 mosaicism. Plots show yield of STR PCR products
(Y-axis) versus allelic size (X-axis). Blue and black peaks represent 6-FAM and TAMRA labeled allelic products, respectively. The dominant paternal
alleles (isodisomy 9) and the minor maternal alleles for informative STR markers D9S925, D9S1118 and D9S1121 that were inherited by the proband are
denoted by symbols (*) and (+), respectively. Control marker D13S325 shows two allelic peaks indicating expected disomy 13
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features, developmental delay, congenital cerebral dyspla-
sia and congenital heart disease. However, in contrast to
other children with a similar low level of T9 mosaicism
[11], growth retardation and developmental delay was par-
ticularly severe in this 22 month old girl and constant
daily care was needed.
Intriguingly, from all the children examined with T9
mosaicism to date, there appears to be no clear correlation
of the level of mosaicism with the severity of the disease
phenotype [11]. One plausible explanation to reconcile
this lack of phenotypic/genotypic correlation is that the
level of T9 mosaicism has only generally been assessed in
peripheral blood lymphocytes and skin. It is possible that
during pre- and post-natal development, the proportion of
T9 cells in the various tissues has altered significantly due
to differences in the intrinsic growth and apoptotic rates
of the normal and trisomic cells. In addition, even within
one tissue or organ, regional differences in T9 mosaicism
may have also arisen. Three case reports provide evidence
to support this notion. In the first case [12], prenatal diag-
nosis of amniocytes detected 100 % T9 whereas postnatal
analysis of kidney, skin, ovary and lung tissue from the de-
ceased child who died at age 6 weeks revealed T9 mosai-
cism levels of 25 %, 15.4 %, 3.7 % and 0 %, respectively. In
two other cases that analysed fetuses that died in utero,
there were also discrepancies noted between the level of
T9 mosaicism in different tissues [13, 14]. Similarly, in the
case presented here, we observed 30 % mosaicism from
placental tissue in the prenatal period by NIPT, but only
17 % and 19 % respectively, in blood and buccal cells by
interphase FISH.
Extensive data collected from pre-implantation genetic
diagnosis cycles [15] demonstrates that chromosomal
trisomy arising in the somatic tissue of an individual has
an early developmental origin. Several mechanisms have
been proposed for the formation of mosaicism including
either a gametal meiotic I/meiotic II chromosome non-
disjunction error and a subsequent trisomy rescue by
anaphase lag in the dividing pre-implantation embryo or
mitotic non-disjunction in one of the early cell divisions
of the cleavage stage embryo [16]. Through these mech-
anisms, the formation of trisomy mosaicism in associ-
ation with uniparental disomy (UPD) is also another
possible outcome [17]. Mosaic embryos can continue to
develop throughout the pre- and post implantation
period leading to the formation of diploid-aneuploid
mosaic fetuses. In this case study, Chr9 STR analyses of
the family pedigree revealed that the proband had inher-
ited two identical copies of paternal Chr9 (isodisomy 9)
and one copy of maternal Chr9 with comparative pater-
nal:maternal Chr9 ratios of approximately 10:1. On this
basis, we conclude that the origin of the T9 mosaicism
in the child was most likely due to a paternal meiotic II
non-disjunction error of Chr9 followed by a post-zygotic
T9 rescue event of the maternally inherited Chr9 in the
initial cleavage divisions of the developing embryo. We
speculate that these two independent Chr9 events in the
pre-implantation period ultimately lead to the develop-
ment of T9 mosaicism in the child, comprising paternal
isodisomy 9 in the majority of somatic cells and T9 in
the remaining somatic cells.
From the literature, there have several prenatal reports
[18, 19] where the fetus has been identified with T9 mosai-
cism in association with maternal UPD 9. Based on re-
cords of all documented UPD 9 cases (http://upd-tl.com/
upd.html), there have been 10 births with maternal UPD 9
and one birth with paternal UPD 9. Clinical examination
of those individuals with maternal UPD 9, which is associ-
ated with maternally imprinted genes, revealed no signifi-
cant disease phenotypes [20]. However, when the maternal
UPD9 was also associated with T9, the patients displayed
typical symptoms characteristic of trisomy 9 mosaicism
syndrome. The one case of paternal UPD 9 was also found
in the context of trisomy 9 mosaicism with the child
exhibiting typical clinical symptoms of trisomy 9 mo-
saicism syndrome [21]. Thus the child reported in this
study represents the second individual identified with
paternal UPD 9, which we identified as isodisomy 9.
Based on the very severe developmental delay exhibited
by this child, in addition to the possibility of variable
levels of T9 in other tissues, we raise the possibility that
recessive genes associated with growth and develop-
ment on Chr9 such as DMRT1, NTRK2 and NTRKR2
[22] may have also contributed to the overall clinical
disease phenotype of this child.
Over many years traditional prenatal diagnosis by
karyotyping and FISH analysis of cultured amniocytes, in
combination with ultrasound, has been relatively successful
in identifying fetuses with T9 mosaicism [13, 23–25].
However, in clinical practice, decisions regarding termin-
ation of pregnancy are extremely difficult because several
follow up studies have shown that the level of trisomy de-
tected prenatally is often much lower in post-natal tissue
[12, 26]. In addition, it is almost impossible to determine
the clinical significance of low-level trisomy in cultured
amniocytes since it could represent either true fetal mosai-
cism or pseudomosaicism as a result of culture artifacts
[27]. The case reported here was additionally confounding
because the low-level T9 originally detected at 15 weeks
gestation by NIPT was not identified by traditional con-
firmation by amniocentesis, cell culture and karyotyping
even at 34 weeks gestation. This suggests that in this case,
culturing of amniocytes may have caused preferential
growth of normal cells over abnormal cells, masking the
low level of T9 mosaicism. This case therefore highlights
the need for direct analysis of the biopsied fetal cells with-
out culture to increase detection sensitivity when low-
level T9 mosaicism is suspected [28].
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Conclusions
In summary, with increasing numbers of pregnant women
undertaking NIPT as the primary test method for com-
mon fetal aneuploidies, this study shows the feasibility of
also detecting a rare chromosomal disorder such as T9
mosaicism syndrome. Apart from T9 mosaicism, T8 mo-
saicism can also develop to term and cause severe disease
phenotypes [29]. While reporting detection of these two
rare chromosomal disorders diseases would extend the
clinical utility of NIPT beyond common autosomal triso-
mies and sex aneuploidies, on a cautionary note, this may
in turn increase the false positive rates since T8 and T9
are often associated with confined placental mosaicism
[30]. Nevertheless NIPT, in conjunction with confirmatory
invasive testing and ultrasound scanning, may ultimately
prove a more robust approach to identify fetuses with
these rare chromosome disease syndromes.
Materials and methods
Noninvasive prenatal testing
Clinical NIPT was performed according to previously de-
scribed methods [5]. In brief, plasma DNA libraries were
generated and subjected to massively parallel sequencing
on the HiSeq2000 platform (Illumina, US) to generate ~8
million (M) 36 bp sequencing reads per sample. Using the
Burrows Wheeler algorithm [31], ~5 M reads were uniquely
and perfectly aligned to the unmasked hg19 reference
genome. After normalization and comparison to reference
data, z-scores were assigned for each chromosome, with a
normal range of −3 < z < 3 for autosomal disomy.
Cytogenetic studies
Metaphase chromosomes were prepared from cultured
PHA-stimulated peripheral blood cells. Karyotypes were
determined from G banded metaphase chromosome
analysis of 100 cells at a resolution of 320 bands. Inter-
face FISH was performed on peripheral blood and buc-
cal cells using 9p SpectrumGreen (locus 305 J7-T7) and
9q SpectrumOrange (locus D9S325) probes (TelVysion,
Abbott Molecular, US) according to the recommended
protocol. At least 100 cells were examined with 9p and
9q probes to determine levels of Chr9 mosaicism.
Quantitative fluorescent PCR analysis
STR markers D9S157, D9S164, D9S288, D9S925, D9S1118,
D9S1121, D9S1677, D9S1874 and D9S2157 with high
heterozygosity indices (>0.7) were selected for Chr9
analysis, with markers D21S1270 and DS13S325 serving
as disomy controls. Forward primers for each STR marker
were labeled with either 6-carboxy fluorescein (6FAM)
or carboxy tetramethylrhodamine (TAMRA). Singleplex
QF-PCR reactions (30 amplification cycles) were performed
using 50 ng of genomic DNA (Kapa Taq HotStart PCR
kit, Kapa Biosystems) according to the manufacturer’s
instructions. Labeled PCR products were analyzed on a
3130 Genetic Analyzer (Applied Biosystems, US) and allelic
peaks plotted as relative fluorescence intensity (Y-axis)
versus size in nucleotides (X-axis).
Consent
Written informed consent was obtained from the parents
of the child for the publication of this report and any ac-
companying images.
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